Business
Presenting at the Biotech Capital Conference
Presenting at the Biotech Capital Conference.
About this update from Scancell Holdings Plc
[{"type":"text","content":"\n \nRNS Number : 8109P Scancell Holdings Plc 23 February 2016 \n\n23 February 2016\n \nScancell Holdings Plc\n(\"Scancell\" or the \"Company\")\n \nScancell to present at the Biotech Capital Conference\n \n \nScancell Holdings plc, ('Scancell' or the 'Company') the developer of novel immunotherapies for the treatment of cancer, announces that the Company will be presenting at the Biotech Capital Conference on Thursday 3 March 2016.\n \nDr Richard Goodfellow will present an update on the Company's immunotherapy platform technologies:\n \n· ImmunoBody® - Potent DNA vaccine technology for use in combination with checkpoint inhibitors or as monotherapy for patients with resected disease\n· Moditope® - Novel immunotherapy that destroys tumours and extends survival without the need for checkpoint inhibition\n \nThe event will commence at 9.00am at 52 Chiswell Street, London, EC1Y 4SD. Attendance is free, with registration via www.biotech-capital.com/conferences.\n \nThe Biotech Capital Conferences are a new institutionally focused platform for listed Biotech companies to reach out to a very active pool of investors. Participants include Biotech investors, investment managers, private client brokers and analysts who want exclusive access to the management of some of the market's most interesting, high growth companies.\n \nA recording of the presentation will be available on the Company's website following the event. \n \nFor Further Information: \n \nScancell Holdings Plc\n\n\n\n\nDr Richard Goodfellow, Joint CEO\nProfessor Lindy Durrant, Joint CEO \n\n\n \n\n\n+ 44 (0) 20 3727 1000\n\n\n\n\n \n\n\n \n\n\n \n\n\n\n\nLarpent Newton\n\n\n \n\n\n \n\n\n\n\nCharles Breese\n\n\n \n\n\n+44 (0) 12 8070 3482\n\n\n\n\n \n\n\n \n\n\n \n\n\n\n\nFTI Consulting\n\n\n \n\n\n \n\n\n\n\nMo Noonan/Simon Conway\n\n\n \n\n\n+ 44 (0) 20 3727 1000\n\n\n\n\n \n \nAbout Scancell \n \nScancell is developing novel immunotherapies for the treatment of cancer based on its ImmunoBody® and Moditope® technology platforms. \n \nScancell's first ImmunoBody®, SCIB1 is being developed for the treatment of melanoma and is being evaluated in a P...